Novo Nordisk is laying off 400 people in Denmark and China so it can overhaul its R&D and speed up the expansion and diversification of products for serious chronic diseases.
Novo Nordisk has doubled its insulin stockpile in the UK, amid patients' fears that a no-deal Brexit could disrupt supplies of the life-saving medicine, its CEO has said.
It all looked so good in 2011 when Eli Lilly agreed a deal with French biotech Adocia to develop an ultra-rapid insulin, in a deal worth up to $165 million.
The European Commission (EC) has approved AstraZeneca’s Bydureon BCise, a new weekly formulation of established GLP-1 diabetes drug with the added benefit of glucose reduct
